acetylcysteine has been researched along with Congenital Thrombotic Thrombocytopenic Purpura in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galstyan, GM; Kalinina, II; Klebanova, EE; Maschan, AA | 1 |
| Beyler, O; Demir, C | 1 |
| Blanquer, M; Díaz-Carrasco, MS; Español, I; García-Candel, F; Gómez-Espuch, J; González, C; Heredia, A; Leal, JD; Martínez, A; Montserrat, J; Moraleda, JM | 1 |
| Huang, F; Kong, D; Li, J; Liu, X; Lu, S; Su, J; Wang, J; Wei, Y; Zhang, Y | 1 |
| Coppo, P; Picod, A; Provôt, F | 1 |
| Gómez-Almaguer, D; Gómez-De León, A; Villela-Martínez, LM; Yáñez-Reyes, JM | 1 |
| Deng, JN; Gao, LL; Huang, MJ; Zhou, JF | 1 |
| de la Rubia, J; Fernández-Zarzoso, M; Gómez-Seguí, I | 1 |
| Coppo, P; Kremer Hovinga, JA; Lämmle, B; Miyata, T; Moake, JL; Vanhoorelbeke, K | 1 |
| Coppo, P; Joly, BS; Veyradier, A | 1 |
| Demir, C; Demircioğlu, S; Doğan, A; Ekinci, Ö | 1 |
| Kamboj, J; Li, GW; Mims, MP; Moake, JL; Rambally, S; Reilly, S; Udden, MM | 1 |
| Knöbl, P | 1 |
| George, JN; Konkle, BA; López, JA | 1 |
| Opat, SS; Shortt, J; Wood, EM | 1 |
| Hochberg-Klein, S; Kalish, Y; Rottenstreich, A; Rund, D | 1 |
| Coppo, P; Froissart, A | 1 |
| De Meyer, SF; Deckmyn, H; Dekimpe, C; Lamprecht, S; Lopez, JA; Pareyn, I; Plaimauer, B; Roodt, J; Tersteeg, C; Van Rensburg, WJ; Vandenbulcke, A; Vandeputte, N; Vanhoorelbeke, K | 1 |
| Andrews, RK; Berndt, MC | 1 |
| Chen, J; Fu, X; Gushiken, FC; López, JA; Moake, JL; Ni, H; Nolasco, L; Reheman, A | 1 |
7 review(s) available for acetylcysteine and Congenital Thrombotic Thrombocytopenic Purpura
| Article | Year |
|---|---|
Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Adrenal Cortex Hormones; Anemia, Hemolytic; Autoantibodies; Clinical Trials as Topic; Forecasting; Humans; Immunologic Factors; Molecular Targeted Therapy; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Rituximab; Single-Domain Antibodies | 2019 |
Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents.
Topics: Acetylcysteine; ADAMTS13 Protein; Adrenal Cortex Hormones; Bortezomib; Drug Repositioning; Humans; Purpura, Thrombotic Thrombocytopenic; Rituximab; Single-Domain Antibodies | 2020 |
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Aptamers, Nucleotide; Autoantigens; Clinical Trials as Topic; Combined Modality Therapy; Crotalid Venoms; Drug Approval; Drug Therapy, Combination; Drugs, Investigational; Fibrinolytic Agents; Humans; Immunologic Factors; Immunosuppressive Agents; Lectins, C-Type; Molecular Targeted Therapy; Multicenter Studies as Topic; Plasma Exchange; Platelet Adhesiveness; Protein Domains; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Single-Domain Antibodies; Treatment Outcome; von Willebrand Factor | 2020 |
Thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Antiviral Agents; Female; Glucocorticoids; HIV Infections; Humans; Immunologic Factors; Immunomodulation; Pregnancy; Pregnancy Complications; Purpura, Thrombotic Thrombocytopenic; Rituximab; Shiga Toxins; Splenectomy | 2017 |
Thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Adult; Age of Onset; Antibodies, Monoclonal; Autoantibodies; Bortezomib; Female; Humans; Immunologic Factors; Male; Mutation; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Sex Characteristics; Single-Domain Antibodies | 2017 |
Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults.
Topics: Acetylcysteine; ADAM Proteins; ADAMTS13 Protein; Adult; Antibodies, Monoclonal, Murine-Derived; Aptamers, Nucleotide; Complement System Proteins; Humans; Immunosuppressive Agents; Plasma Exchange; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Remission Induction; Rituximab; Single-Domain Antibodies; Splenectomy; Treatment Outcome; von Willebrand Factor | 2014 |
Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
Topics: Acetylcysteine; ADAM Proteins; ADAMTS13 Protein; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Cyclosporine; Humans; Plasma Exchange; Platelet Aggregation Inhibitors; Prognosis; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Recurrence; Risk; Rituximab; Splenectomy; Steroids; Treatment Outcome; Vincristine; von Willebrand Factor | 2015 |
13 other study(ies) available for acetylcysteine and Congenital Thrombotic Thrombocytopenic Purpura
| Article | Year |
|---|---|
[Treatment of thrombotic thrombocytopenic purpura].
Topics: Acetylcysteine; Bortezomib; Child; Cyclosporine; Humans; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Rituximab | 2021 |
Use of n-acetylcysteine therapy in patients with relapsed refractory thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Anemia, Hemolytic; Humans; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Thrombosis; von Willebrand Factor | 2023 |
N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study.
Topics: Acetylcysteine; ADAMTS13 Protein; Humans; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Rituximab | 2023 |
Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.
Topics: Acetylcysteine; Adult; Cohort Studies; Hospital Mortality; Humans; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Retrospective Studies | 2023 |
[N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura: a case report].
Topics: Acetylcysteine; Humans; Purpura, Thrombotic Thrombocytopenic | 2020 |
Relapsed/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report.
Topics: Acetylcysteine; Adult; Female; Humans; Purpura, Thrombotic Thrombocytopenic; Recurrence | 2018 |
Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report.
Topics: Acetylcysteine; ADAM Proteins; ADAMTS13 Protein; Adult; Female; Humans; Platelet Count; Purpura, Thrombotic Thrombocytopenic | 2014 |
N-Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; Female; Humans; Purpura, Thrombotic Thrombocytopenic | 2014 |
N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?
Topics: Acetylcysteine; Female; Humans; Purpura, Thrombotic Thrombocytopenic | 2014 |
The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura.
Topics: Acetylcysteine; ADAMTS13 Protein; Autoantibodies; Female; Humans; Male; Middle Aged; Purpura, Thrombotic Thrombocytopenic | 2016 |
Topics: Acetylcysteine; ADAMTS13 Protein; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Gene Deletion; Male; Mice; Mice, Inbred C57BL; Papio; Protein Multimerization; Purpura, Thrombotic Thrombocytopenic; von Willebrand Factor | 2017 |
Thrombotic thrombocytopenic purpura: reducing the risk?
Topics: Acetylcysteine; ADAM Proteins; ADAMTS13 Protein; Animals; Humans; Membrane Glycoproteins; Mice; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Purpura, Thrombotic Thrombocytopenic; Thrombosis; von Willebrand Factor | 2011 |
N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.
Topics: Acetylcysteine; ADAMTS13 Protein; Animals; Anti-Bacterial Agents; Endothelial Cells; Humans; Male; Metalloendopeptidases; Mice; Mice, Inbred C57BL; Mice, Knockout; Plasma; Platelet Aggregation; Protein Multimerization; Purpura, Thrombotic Thrombocytopenic; Ristocetin; Thrombosis; von Willebrand Factor | 2011 |